Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 4/20 | 0.45 |
| ▸ | CNR2 | P34972 | 6/20 | 0.37 |
| ▸ | DPP4 | P27487 | 5/20 | 0.37 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.34 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3675526 | 0.98 | MME (0.44) | MMECNR2DPP4CACNA1HADRB2 | |
| SCHEMBL18131263 | 0.95 | MME (0.41) | MMECNR2DPP4CACNA1HCNR1 | |
| SCHEMBL3151070 | 0.90 | — | — | |
| SCHEMBL19749002 | 0.82 | MME (0.38) | MMECNR2DPP4ALDH1A1 | |
| SCHEMBL3830401 | 0.80 | DPP4 (0.41) | MMEDPP4ALDH1A1 | |
| SCHEMBL4725793 | 0.80 | KDM4E (0.34) | MME | |
| SCHEMBL23573562 | 0.79 | MME (0.37) | MMEADRB2CYP2C19ALDH1A1HTT | |
| SCHEMBL976812 | 0.79 | MME (0.44) | MMECNR2DPP4CACNA1HALDH1A1 | |
| SCHEMBL14165607 | 0.79 | ALDH1A1 (0.42) | MMEADRB2CYP2C19ALDH1A1HTT | |
| SCHEMBL16333537 | 0.77 | CYP2C19 (0.34) | MMEADRB2CYP2C19ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1898234-A | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | INCYTE CORP (US) | 2007-01-17 | — | — | CN | claimed |
| US-20210198239-A1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2021-07-01 | — | — | US | disclosed |
| US-9695162-B2 | Sweet flavor modifier | SENOMYX, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-20170044182-A1 | FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF | FORUM PHARMACEUTICALS INC. | 2017-02-16 | — | — | US | disclosed |
| US-20170029416-A1 | SWEET FLAVOR MODIFIER | SENOMYX, INC. | 2017-02-02 | — | — | US | disclosed |
| WO-2014130513-A1 | SWEET FLAVOR MODIFIER | SENOMYX, INC. (US) | 2014-08-28 | — | — | WO | disclosed |
| EP-2459535-A1 | PYRIDINE AND PYRAZINE DERIVATIVES AS PROTEIN KINASE MODULATORS | Novartis AG (CH) | 2012-06-06 | — | — | EP | disclosed |
| CN-1898234-A | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | INCYTE CORP (US) | 2007-01-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198239-A1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | ENTPD5, ADORA2A, ENTPD1 | MME 460/4885CNR2 276/4885DPP4 610/4885 |
| US-20170044182-A1 | FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF | SMN1; SMN2, FUS, SYNCRIP | MME 777/4885CNR2 4748/4885DPP4 1451/4885 |
| US-20170029416-A1 | SWEET FLAVOR MODIFIER | TAS2R5, TAS2R10, TAS2R50 | MME 2701/4885CNR2 3761/4885DPP4 387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.